Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Technology ID
TAB-5070

C8166-45 Cells

E-Numbers
E-272-2007-0
Lead Inventors
Franchini, Genoveffa
Co-Inventors
Salahuddin, Syed
Wong-Staal, Flossie
Gallo, Robert
Markham, Phillip
Kalyanaraman, V
Applications
Research Materials
Therapeutic Areas
Oncology
Infectious Disease
Development Stages
Analytical Assay Performance Stage
Lead IC
NCI
ICs
NCI

Summary:

The National Cancer Institute (NCI) seeks licensees for a human T-cell line, C8166-45, transformed by HTLV-1. C8166-45, also known as C63/CRII-2, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth.

Description of Technology:                                                                          

Human T-cell leukemia virus type 1 (HTLV-1) was the first human retrovirus reported and is recognized as an etiological agent of adult T-cell leukemia (ATL). However, only a small percentage of individuals develop symptomatic ATL which carries a poor prognosis. The latency period can last for decades and universal screening for HTLV-1 infection has ceased. Thus, the C8166-45 cell line is a necessary component for understanding the mechanisms of HTLV-1 infection and improving clinical outcomes.

NCI researchers derived C8166-45 by cocultivation or fusion of umbilical cord blood lymphocyte with T-cells cultures from leukemia-lymphoma patients. It is highly permissive to HIV-1 infection and characterized for its suitability in replication-competent lentiviral (RCL) assays to assess its safety for gene therapy products, such as lentiviral vectors. This cell line is highly useful in studying viral protein interactions, immortalization of human T-cells, and HIV replication.

NCI is seeking parties to non-exclusively license the C8166-45 cell line.

Potential Commercial:  

  • Investigation of HTLV pathogenesis and replication
  • Studies of virus-induced T-cell transformation
  • Studies of HTLV expression regulation by human T-cells
  • Studies of HIV replication

Competitive Advantages:

  • Contains a low amount of viral proteins
  • Does not release detectable virus particles
  • Suitable for testing RCL assay sensitivity

Request More Info

Licensing Contacts
Dattaroy, Diptadip
diptadip.dattaroy@nih.gov

Publications

  • DeBoer J, et al. Alterations in the nuclear proteome of HIV-1 infected T-cells. (PMID 25240327)
  • Salahuddin SZ, et al. Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. (PMID 6412453)
  • Cornetta K, et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. (PMID 28970045)

Collaborations

  • Licensing

Collaboration Description

  • The NCI seeks licensing for the C8166-45 cell line.
Date Published